- Conditions
- Migraine
- Interventions
- Rimegepant, Various, No intervention
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 49 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 10,510
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vascular Aging
- Interventions
- Lactobacillus Plantarum 299v in fermented oat drink, Heat-Killed Placebo control fermented drink
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
- Interventions
- Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2030
- U.S. locations
- 5
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
- Conditions
- Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
- Interventions
- Dostarlimab, Niraparib
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autism Spectrum Disorder, Neurodevelopmental Disorders
- Interventions
- Self-Determined Learning Model of Instruction (SDLMI)
- Behavioral
- Lead sponsor
- Health Resources and Services Administration (HRSA)
- Federal
- Eligibility
- 13 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Davis, California • Lawrence, Kansas • Seattle, Washington
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Costa Mesa, California • La Jolla, California • Orange, California + 19 more
- Conditions
- Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Encinitas, California • Irvine, California • La Jolla, California + 12 more
- Conditions
- Mood Disorders
- Interventions
- Mindfulness-Based Intervention (MBI), Health and Wellness Intervention (HWI)
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 11 Years to 14 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Internalizing Behavior, Externalizing Behavior, Child Permanency, Parenting, Parent Stress, Service Utilization
- Interventions
- KEEP-CK
- Behavioral
- Lead sponsor
- Oregon Social Learning Center
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Lower Limb Amputation Above Knee (Injury), Congenital Amputation of Lower Limb, Lower Limb Amputation Knee
- Interventions
- Kenevo or C-Leg 4, Non microprocessor controlled knee (NMPK)
- Device
- Lead sponsor
- Otto Bock Healthcare Products GmbH
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 85 more
- Conditions
- Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
- Interventions
- GNSC-001, transient immune-modulation, Placebo
- Genetic · Drug
- Lead sponsor
- Genascence Corporation
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • La Mesa, California • San Diego, California + 6 more
- Conditions
- Medication Adherence, Hypertension
- Interventions
- My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- MASH
- Interventions
- RO7790121
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Marietta, Georgia • Bastrop, Louisiana + 8 more
- Conditions
- Alpha Thalassemia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Nivolumab, Temozolomide
- Drug
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Wilson's Disease
- Interventions
- VTX-801
- Genetic
- Lead sponsor
- Vivet Therapeutics SAS
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • New Haven, Connecticut • Orlando, Florida + 3 more
- Conditions
- Surgery, Aging, Health Care Utilization, Frailty
- Interventions
- Process Mapping: Observations, Process Mapping: Interviews, Process Mapping: Focus Group, Participatory Design
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- Standard of Care Biopsy
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 29 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
- Interventions
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Drug
- Lead sponsor
- Lantern Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
- Interventions
- Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2027
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
- Conditions
- Breast Cancer
- Interventions
- Talazoparib, Sacituzumab Govitecan
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
- Diagnostic Test
- Lead sponsor
- Biotheranostics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 105
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 84 more